CSIMarket Company Name, Ticker, Competitors, else..
 
Aptose Biosciences Inc   (APTO)
Other Ticker:  
 
 
Price: $2.2200 $-0.16 -6.723%
Day's High: $2.48 Week Perf: -18.98 %
Day's Low: $ 2.22 30 Day Perf: -21.28 %
Volume (M): 80 52 Wk High: $ 6.60
Volume (M$): $ 178 52 Wk Avg: $2.12
Open: $2.48 52 Wk Low: $0.36



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Aptose Biosciences Inc


   Company Address: 251 Consumers Road, Suite 1105 Toronto 0 ON
   Company Phone Number: 479-9828   Stock Exchange / Ticker: NASDAQ APTO
   APTO is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Anavex Life Sciences Corp

Anavex Life Sciences Corp's EPS Soars by 454.76% Despite Decline in Revenue during Q4 2023


Date: November 30, 2023
Anavex Life Sciences Corp, a renowned Biotechnology and Pharmaceuticals company, recently reported its financial results for the fiscal fourth quarter of 2023. Despite a sharp decline in revenue, the company's earnings per share (EPS) witnessed a commendable surge. Let's delve into the details of these results and analyze what this means for the future of the company.
In the fiscal fourth quarter of 2023, Anavex Life Sciences Corp reported a staggering EPS growth of 454.76%. The EPS rose to $0.48 per share, compared to $0.09 per share in the same quarter a year ago. Moreover, the company was able to turn its EPS positive, bouncing back from a loss of $-0.14 per share in the prior quarter. This robust growth in earnings is undoubtedly a positive sign for shareholders and investors.
Twist Bioscience Corporation

Twist Bioscience Corporation Successfully Narrows Deficit, Demonstrating Promising Financial Recovery from July to September 2023

Twist Bioscience Corporation, a leading biotechnology and pharmaceutical company, has showcased strong financial performance in the third quarter of 2023. The company reported a decrease in loss per share, improved income per share, and a significant increase in revenue.
Compared to the previous year, Twist Bioscience Corporation reduced its loss per share from $0.81 to $0.80. Additionally, income per share improved from $1.01 to $0.80 from the previous quarter. These positive results indicate the company's efforts to minimize losses and improve profitability.
Agentix Corp

Article Title: FWDR Announces Second Quarter 2024 Performance, Exhibiting Growth Potential in Biotechnology and Pharmaceuticals Sector



In the fast-paced world of Biotechnology and Pharmaceuticals, where industry leaders often dominate the headlines, it is crucial to keep an eye on lesser-known businesses that may harbor potential for growth and success. One such company, FWDR, recently announced its financial results for the second quarter of 2024, providing some encouraging news and offering investors assurance about its future prospects.
Operating Shortfall Improvement:
FWDR disclosed an operating shortfall of $-0.353155 million for Q2 2024. Although it cannot be considered a significant financial achievement on its own, the fact that it represents an improvement compared to the same period in the previous year is noteworthy. In Q2 2023, FWDR had reported a larger operating shortfall of $-0.42433 million. This improvement indicates the company's commitment to enhancing its financial performance and marks a step in the right direction.
Mymetics Corporation

Mymetics Corporation Faces Challenging Performance in Q3 2023 as Earnings Decline

Financial News Report: Mymetics Corporation Earnings Decline in Q3 2023
Mymetics Corporation, a leading company in the XYZ industry, recently released its financial earnings report for the third quarter of 2023. The results showcase a decline in earnings and revenue compared to the previous year and the previous reporting period.
During the third quarter of 2023, Mymetics Corporation reported earnings per share (EPS) of $0.00. This is the same figure as the previous year but a decrease compared to the previous reporting period. This stagnant growth in earnings per share suggests that the company's profitability remained unchanged.
Redwoods Acquisition Corp

Redwoods Acquisition Corp Roars into Action, Defying Third Quarter Slump

The third quarter financial results for Redwoods Acquisition Corp in 2023 have been released, revealing an operating deficit of -$0.292227 million. This is a significant decrease compared to the operating deficit of -$0.179726 million in the same quarter of the previous year, indicating a decline in the company's financial performance.
To better understand the impact of these results, it is important to analyze the bottom-line figure, which shows a -52.71 percent reduction to $0.729 million in the third quarter of 2023 from the third quarter of 2022. This reduction highlights a substantial decline in the company's earnings during this period.





 




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com